Search research articles
Contact Us
Filters
Showing results (1-10 of 162) with videos related to
Page
of 17
Sort By:
Digestive Diseases (Basel, Switzerland)
|
February 2, 2017
Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost
Ann Gils
Therapeutic Drug Monitoring
|
March 19, 2019
Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases
Erwin Dreesen, Ann Gils
Journal of Crohn'S & Colitis
|
March 24, 2017
Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?
Erwin Dreesen, Ann Gils
Current Pharmaceutical Design
|
December 1, 2017
Risk Assessment and Monitoring of Antibody Responses to Biosimilars in Chronic Inflammatory Diseases
Iris Detrez, Ann Gils
Journal of Crohn'S & Colitis
|
August 3, 2016
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
Iris Detrez, Ann Gils
Alimentary Pharmacology & Therapeutics
|
October 16, 2018
Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' reply
Erwin Dreesen, Ann Gils
Thrombosis Research
|
July 31, 2012
Is there any need for a TAFI(a) inhibitor as thrombolytic drug?
Ellen Vercauteren, Ann Gils
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 30, 2019
Reply
Erwin Dreesen, Ann Gils
Frontline Gastroenterology
|
January 8, 2013
Value of drug level testing and antibody assays in optimising biological therapy
Séverine Vermeire, Ann Gils
Current Medicinal Chemistry
|
September 24, 2004
Plasminogen activator inhibitor-1
Ann Gils, Paul J Declerck
Page
of 17
Search research articles
Search
Showing results (1-10 of 162) with videos related to
Sort By:
Page
of 17
Digestive Diseases (Basel, Switzerland)
|
February 2, 2017
Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost
Ann Gils
Therapeutic Drug Monitoring
|
March 19, 2019
Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases
Erwin Dreesen, Ann Gils
Journal of Crohn'S & Colitis
|
March 24, 2017
Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?
Erwin Dreesen, Ann Gils
Current Pharmaceutical Design
|
December 1, 2017
Risk Assessment and Monitoring of Antibody Responses to Biosimilars in Chronic Inflammatory Diseases
Iris Detrez, Ann Gils
Journal of Crohn'S & Colitis
|
August 3, 2016
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
Iris Detrez, Ann Gils
Alimentary Pharmacology & Therapeutics
|
October 16, 2018
Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' reply
Erwin Dreesen, Ann Gils
Thrombosis Research
|
July 31, 2012
Is there any need for a TAFI(a) inhibitor as thrombolytic drug?
Ellen Vercauteren, Ann Gils
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 30, 2019
Reply
Erwin Dreesen, Ann Gils
Frontline Gastroenterology
|
January 8, 2013
Value of drug level testing and antibody assays in optimising biological therapy
Séverine Vermeire, Ann Gils
Current Medicinal Chemistry
|
September 24, 2004
Plasminogen activator inhibitor-1
Ann Gils, Paul J Declerck
Page
of 17